Inicio › Linfoma de Burkitt › Minnesota
Ensayos clínicos de Linfoma de Burkitt en Minnesota
10 estudios sobre Linfoma de Burkitt buscan participantes en Minnesota.
Ciudades en Minnesota
Texto oficial del estudio (inglés)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Essentia Health Cancer Center, Duluth
- Abbott-Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Rochester
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospitals and Clinics of Minnesota, Minneapolis
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
ReclutandoFase 2
Hasta los 75 · Todos los sexos · Actualizado el 6 jul 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
ReclutandoFase 2
Hasta los 60 · Todos los sexos · Actualizado el 25 jun 2026 · NCT03314974De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.